Axogen Inc. (AXGN)
AXGN trades on Nasdaq in Health Care, Biotechnology: Electromedical & Electrotherapeutic Apparatus. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/805928/000080592826000031/0000805928-26-000031-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | AXGN on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0000805928 |
| SEC industry code | Electromedical & Electrotherapeutic Apparatus |
| Incorporated in | MN |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $225.2M |
| Net income | -$15.7M |
| Operating income | -$7.8M |
| Net margin | -7.0% |
| Operating margin | -3.5% |
| Revenue growth | +20.2% |
| Cash | $35.5M |
| Total assets | $221.7M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 14.7× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-10-28 |
| Cash and burn | $328.9M cash; operating cash flow $7.1M a quarter. | Report 2026-09-30 |
| Shares outstanding | 59,730,715 (2026-10-26); 46,122,289 a year earlier; 43,043,606 three years earlier. | Cover page 2026-10-26 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 3 424B5 takedowns, 3 at the market | Latest 2026-09-10 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Deloitte & Touche LLP, Tampa, Florida, United States | PCAOB Form AP 2026-03-11 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $19.9M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $75.8M | $2.3M | $16.5M | $328.9M | $0 | $266.9M | 10-Q 2026-10-28 |
| Q2 2026 2026-06-30 | $69.7M | -$1.5M | $7.2M | $94.6M | $0 | $251.2M | 10-Q 2026-07-29 |
| Q1 2026 2026-03-31 | $61.5M | -$19.6M | $1.6M | $82.7M | $0 | $238.1M | 10-Q 2026-04-28 |
| Q4 2025 2025-12-31 | $59.9M | -$13.2M | $3.0M | $35.5M | $48.4M | $225.2M | 10-K 2026-02-24 |
| Q3 2025 2025-09-30 | $60.1M | $708K | $3.2M | $23.9M | $48.2M | $214.7M | 10-Q 2026-10-28 |
| Q2 2025 2025-06-30 | $56.7M | $579K | $7.7M | $20.0M | $47.9M | $203.3M | 10-Q 2026-07-29 |
| Q1 2025 2025-03-31 | $48.6M | -$3.8M | -$13.2M | $18.1M | $47.7M | $194.5M | 10-Q 2026-04-28 |
| Q4 2024 2024-12-31 | $49.4M | $450K | $8.7M | $27.6M | $47.5M | $187.3M | 10-K 2026-02-24 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-09-10 |
| Latest annual report FORM 10-K | 10-K | 2026-02-24 |
| Latest quarterly / interim FORM 10-Q | 10-Q | 2026-10-28 |
| Latest current report FORM 8-K | 8-K | 2026-11-09 |
| Latest proxy AXGN DEFINITIVE PROXY STATEMENT | DEF 14A | 2026-04-29 |
Source: SEC EDGAR submissions feed, 1,001 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +11.8% |
| 1 month | +54.6% |
| 3 months | +16.4% |
| Year to date | +70.9% |
| 1 year | +132.7% |
| From 52-week high | -4.6% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Electromedical & Electrotherapeutic Apparatus
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| TMDX | TransMedics Group Inc. | $92.21 | +0.91% | $3.2B |
| LIVN | LivaNova PLC | $92.44 | +1.23% | $5.1B |
| CNMD | CONMED Corporation | $49.35 | -2.45% | $1.5B |
| CBLL | CeriBell Inc. | $26.42 | +1.07% | $1.0B |
| INMD | InMode Ltd. | $13.15 | -0.90% | $755.9M |
| CV | CapsoVision Inc. | $6.47 | +7.30% | $346.9M |
| ELMD | Electromed Inc. | $23.10 | -5.02% | $188.8M |
| FOCL | EDAP TMS S.A. | $3.17 | -2.39% | $149.7M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier